Superior Planning, LLC’s Nurix Therapeutics NRIX Stock Holding History

Superior Planning, LLC’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.29K	Buy	+181	New	+$4.51K	﹤0.01%	1262

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.6B AUM 38.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Superior Planning, LLC's NRIX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Nurix Therapeutics (NRIX) in Q3 2026: 181 shares worth $4.29K. The stake represents ﹤0.01% of the portfolio and ranks #1262 among its holdings.

110 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

Superior Planning, LLC held 181 shares of Nurix Therapeutics worth $4.29K as of Q3 2026.
Nurix Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Nurix Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1262 holding.
110 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.